Alfarona - Instructions For Use, Indications, Doses, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Alfarona

Instructions for use:

1. 1. Release form and composition
2. 2. Indications for use
3. 3. Contraindications
4. 4. Method of application and dosage
5. 5. Side effects
6. 6. Special instructions
7. 7. Drug interactions
8. 8. Analogs
9. 9. Terms and conditions of storage
10. 10. Terms of dispensing from pharmacies

Prices in online pharmacies:

from 998 rub.

Buy

Alfarona is a recombinant human interferon alpha-2b with immunomodulatory, antimicrobial, antitumor, antiviral, anti-inflammatory effects.

Release form and composition

Dosage forms:

• Lyophilisate for the preparation of a solution for injection and topical application: a porous hygroscopic mass of almost white or white color (in vials: in a cardboard box 1, 5, 10 or 20 bottles; in a blister or cassette contour packaging of 1, 5, 10 or 20 bottles, in a cardboard box 1 package);
• Lyophilisate for preparation of a solution for intranasal use: porous mass of light yellow or white, hygroscopic; after dissolution - a clear light yellow or colorless liquid without foreign inclusions and sediment (in bottles, in a cardboard box 1 or 5 bottles complete with 1 or 5 bottles or ampoules (5 ml each) of water for injection).

The active substance of Alfarona is human recombinant interferon alpha-2b:

• 1 vial of lyophilisate for solution for injection and topical use: 0.5 million international units (IU), 1 million, 3 million or 5 million IU;
• 1 bottle with lyophilisate for preparation of solution for intranasal administration: 0.05 million IU.

Auxiliary components: sodium chloride, sodium phosphate disubstituted, polyglucin, sodium phosphate monohydrate 2-water.

Indications for use

Lyophilisate for preparation of solution for injection and topical use

As part of complex therapy in adults:

• Acute long-term hepatitis B, a chronic form of active hepatitis B or D with or without signs of liver cirrhosis;
• Moderate or severe form of acute viral hepatitis B - from the moment of onset of symptoms until the fifth day of jaundice (appointment in a later period is less effective, and in case of cholestatic course and developing hepatic coma, it is completely ineffective);
• Chronic viral hepatitis C;
• Viral conjunctivitis, keratitis, keratoconjunctivitis, keratouveitis;
• Viral meningoencephalitis (herpetic, adenoviral, enterovirus, influenza, mumps), viral-bacterial and mycoplasma etiology;
• Stage IV malignant tumor of the kidney;
• Primary reticulosis, fungal mycosis and other malignant skin lymphomas;
• Squamous and basal cell carcinoma of the skin;
• Kaposi's sarcoma;
• Hairy cell leukemia;
• Keratoacanthoma;
• Histiocytosis X;
• Chronic myeloid leukemia;
• Subleukemic myelosis;
• Multiple sclerosis;
• Essential thrombocytopenia.

The use of Alfarona in children as part of complex therapy:

• Acute lymphoblastic leukemia - after completion of inductive chemotherapy at 4-5 months of remission;
• Respiratory papillomatosis of the larynx.

Lyophilisate for preparing a solution for intranasal administration

Application is indicated in adults and children for the prevention and treatment of the initial stages of influenza, acute respiratory viral infections (ARVI).

Contraindications

• Severe forms of allergic pathologies;
• Individual intolerance to the components of the drug and other interferons.

In addition, the appointment of a lyophilisate for the preparation of a solution for injection and topical application is contraindicated during pregnancy.

Method of administration and dosage

Lyophilisate for preparation of a solution for injection and local use The

ready-made solution of lyophilisate is intended for intramuscular (i / m), subcutaneous (s / c), subconjunctival administration and administration under the or into the lesion, as well as for local use.

To prepare the solution, water for injection should be added to the contents of the vial before direct use in the following proportion: for intramuscular injection and injection into the focus - 1 ml, for subconjunctival administration and local application - 5 ml. The dissolution period should not exceed 4 minutes. The resulting solution should have a transparent structure without any inclusions.

Do not store the diluted drug!

Recommended dosage for intramuscular and subcutaneous administration:

• Acute hepatitis B: 1 million IU 2 times a day for 5-6 days, then - in the same dose 1 time a day for 5 days. To achieve a clinical effect, the course of treatment can be continued after a biochemical blood test at a dose of 1 million IU once every 3-4 days for 14 days. Heading dose should not exceed 15-21 million IU;
• Chronic and acute protracted active hepatitis B (without signs of liver cirrhosis and delta infection): 1 million IU once every 3-4 days for 1-2 months. In the absence of a therapeutic effect after this course of treatment, the patient should be prescribed 2-3 similar courses with a break of 1-6 months or continue the started course of treatment up to 3-6 months;
• Chronic active hepatitis D without symptoms of liver cirrhosis: 0.5-1 million IU per day every 3-4 days for a month. A second course - in 1-6 months;
• Chronic active hepatitis B and D with signs of liver cirrhosis: 0.25-0.5 million IU per day every 3-4 days, the course is 1 month. Repeated courses are prescribed with the development of signs of decompensation with an interval of 2 months or more;
• Chronic viral hepatitis C: adults - 3 million IU 3 times every 7 days, children - at the rate of 3 million IU per 1 m2 ^of body surface, but not more than 3 million IU 3 times every 7 days. The course of treatment is 9 months;
• Malignant tumor of the kidney: 3 million IU 1 time per day for 10 days. The course is repeated with an interval of 21 days from 3 to 9 or more times. The total amount of the drug is 120-300 million IU or more;
• Hairy cell leukemia: 3-6 million IU once a day for 2 months. When the hemogram is normalized, the dose is reduced to 1-2 million IU per day. Maintenance therapy - 3 million IU 1 time in 3-4 days for 1.5 months. The total dose of the drug is 420-600 million IU and more;
• Acute lymphoblastic leukemia in children within 4-5 months of remission after completion of inductive chemotherapy: in combination with maintenance chemotherapy - 1 million IU 1 time in 7 days for 6 months, then 1 time in 14 days in the same dose in within 24 months;
• Chronic myeloid leukemia: 3 million IU per day or 6 million IU every other day, the course of treatment is 2.5-6 months;
• Histiocytosis X: 3 million IU per day, the course of therapy is 1 month. Within 12-36 months, the course is repeated every 1-2 months;
• Subleukemic myelosis, essential thrombocytopenia (for the purpose of correcting hyperthrombocytosis): 1 million IU once a day or every other day for 20 days;
• Kaposi's sarcoma, malignant lymphoma: 3 million IU per day for 10 days in combination with glucocorticosteroids and cytostatics (cyclophosphamide, prospidin);
• Tumor stage of fungal mycosis, reticulosarcomatosis: it is advisable to alternate intramuscular administration at a dose of 3 million IU and intralesional administration at a dose of 2 million IU, the course of treatment is 10 days. When the temperature rises above 39 ° C and exacerbation of the condition in patients with fungal mycosis in the erythrodermic stage, the administration of Alfarona should be canceled. In the absence of the desired effect, the appointment of a repeated course in 10-14 days is indicated. The maintenance dose is 3 million IU once every 7 days for 1.5 months;
• Respiratory papillomatosis of the larynx (the next day after surgery to remove papillomas): 0.1-0.15 million IU per 1 kg of patient weight per day for 45-50 days, then - in the same dose 3 times every 7 days in within a month. The course is repeated 2 more times with an interval of 2-6 months;
• Multiple sclerosis: with pyramidal syndrome - 1 million IU 3 times a day, with cerebellar syndrome - 1 million IU 1-3 times a day. The course of treatment is 10 days. Then the administration of the same dose is prescribed once every 7 days for 5-6 months. The total dose is 50-60 million IU.

With a high pyrogenic reaction (39 ° C and above), the introduction of Alfarona is recommended to be accompanied by the use of indomethacin.

With keratoacanthoma, squamous cell and basal cell carcinoma, the drug is administered under the lesion (perifocal) at a dose of 1 million IU 1 time per day for 10 days. Patients with severe local inflammatory reactions are shown perifocal administration in 1-2 days. If necessary, cryodestruction is performed after a course of treatment.

For keratoiridocyclitis and stromal keratitis, 0.5 ml of the solution is injected subconjunctivally at a dose of 0.06 million IU every other day or daily under local anesthesia with a 0.5% dicain solution. The course of therapy is 15-25 injections.

For topical use, the lyophilisate is dissolved in 5 ml of 0.9% sodium chloride solution for injection. For storage, the solution is placed (in compliance with the rules of asepsis and antiseptics) in a sterile bottle and stored in a refrigerator (temperature 4-10 ° C) for no more than 12 hours.

With superficial keratitis and conjunctivitis, Alfaron is prescribed topically in the form of applying 2 drops to the conjunctiva of the affected eye 6-8 times a day. The number of instillations should be reduced as inflammation processes decrease up to 3-4 times a day. The duration of treatment is 14 days.

Lyophilisate for preparation of a solution for intranasal administration The

finished solution is injected intranasally into each nasal passage.

To prepare the solution, 5 ml of water for injection is added to the contents of the bottle.

It is necessary to start using it when the first signs of influenza and ARVI diseases appear.

The recommended dosage regimen has age restrictions:

• Adults: 3 drops 5-6 times a day (single dose - 0.003 million IU, daily dose - 0.015-0.018 million IU);
• Newborns and children under 1 year old: 1 drop 5 times a day (single dose - 0.001 million IU, daily dose - 0.005 million IU);
• Children aged 1-3 years: 2 drops 3-4 times a day (single dose - 0.002 million IU, daily dose - 0.006-0.008 million IU);
• Children from 3 to 14 years old: 2 drops 4-5 times a day (single dose - 0.002 million IU, daily dose - 0.008-0.01 million IU).

Duration of treatment is 5 days.

Prevention of ARVI and influenza is carried out in a dose appropriate to the patient's age: after contact with the patient and / or hypothermia - 2 times a day for 5-7 days; with a seasonal increase in morbidity - 1 time (in the morning) per day, in 1-2 days. With a single contact, you can limit yourself to one instillation. Prophylaxis courses can be repeated as needed.

For even distribution of the solution in the nasal cavity, the wings of the nose should be massaged after instillation.

Side effects

Lyophilisate for solution for injection and topical use

• Parenteral administration: possibly - fatigue, chills, fever, pruritus, rash, leukopenia, thrombocytopenia;
• Chipping of the lesion: local inflammatory reactions;
• Local application to the mucous membrane of the eye: possibly - hyperemia of the mucous membrane of the eye, conjunctival infection, edema of the conjunctiva of the lower fornix.

Lyophilisate for preparation of solution for intranasal administration

Side effects have not been established.

special instructions

When leukopenia or thrombocytopenia appears against the background of parenteral administration, the patient needs to conduct a laboratory blood test 2-3 times a week.

The use of the drug should be discontinued in case of development of significant local or general side effects when applied to the conjunctiva of the eyes.

Drug interactions

Lyophilisate for preparation of a solution for intranasal administration

The simultaneous use of vasoconstrictor intranasal agents is not recommended, as this contributes to excessive drying of the mucous surface of the nasal passages.

Analogs

Alfarona's analogs are: Viferon, Interal-P, Interferal, Layfferon, Reaferon-EC-Lipint.

Terms and conditions of storage

Keep out of the reach of children.

Store in a dark, dry place at temperatures up to 10 ° C.

Shelf life is 2 years.

The ready-made solution can be stored in the refrigerator for up to 10 days, without allowing freezing.

Terms of dispensing from pharmacies

Dispensed by prescription.

Alfarona: prices in online pharmacies

Drug name Price Pharmacy

Alfarona 3 million IU lyophilisate for preparation of solution for injection and topical application 5 pcs. 998 RUB Buy

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!